TABLE 1.
Characteristics of all kidney transplant patients included in the study
| June–November 2021 | December 2021–February 2022 | P | |
|---|---|---|---|
| KT infected/KT population, n (%) | 27/952 (2.8) | 117/961 (12.1) | <0.001 |
| Males, n (%) | 17 (63) | 73 (62.4) | 0.95 |
| Recipient age, median [IQR], y | 57 [47–65] | 58 [47–67] | 0.56 |
| Time post-KT to COVID-19, median [IQR], mo | 88 [44–123] | 83 [30–184] | 0.95 |
| Vaccination, n (%) | 26 (96.3) | 112 (96.6) | 0.94 |
| Two doses of vaccine, n (%) | 23 (88.5) | 7 (6.2) | <0.001 |
| Three doses of vaccine, n (%) | 3 (11.5) | 105 (93.8) | <0.001 |
| Type of third dose of vaccine | |||
| mRNA-1273 Moderna, n (%) | 3 (100) | 74 (70.5) | 0.15 |
| BNT162b2 Pfizer-BioNTech, n (%) | 0 | 30 (29.4) | 0.15 |
| Immunosuppressive therapy at COVID-19 diagnosis | |||
| Prednisone, n (%) | 25 (92.6) | 110 (94) | 0.78 |
| Tacrolimus, n (%) | 25 (92.6) | 108 (92.3) | 0.96 |
| Mycophenolate, n (%) | 22 (81.5) | 95 (81.2) | 0.97 |
| mTOR inhibitors, n (%) | 4 (14.8) | 12 (10.3) | 0.49 |
| Cyclosporine, n (%) | 1 (3.7) | 7 (6) | 0.64 |
| Immunosuppressive therapy within 2 y pre-COVID-19 diagnosis | |||
| Thymoglobulin, n (%) | 4 (14.8) | 11 (9.4) | 0.41 |
| Basiliximab, n (%) | 1 (3.7) | 6 (5.2) | 0.75 |
| Rituximab, n (%) | 0 | 1 (0.7) | 0.62 |
| Clinical features | |||
| Asymptomatic, n (%) | 3 (11.1) | 26 (22.2) | 0.19 |
| Fever, n (%) | 15 (55.6) | 43 (36.8) | 0.07 |
| Upper respiratory tract symptoms, n (%) | 16 (59.3) | 85 (72.6) | 0.17 |
| Gastrointestinal symptoms, n (%) | 8 (29.6) | 8 (6.8) | 0.001 |
| Pneumonia, n (%) | 8 (29.6) | 19 (16.2) | 0.11 |
| COVID-19 management | |||
| Hospitalized, n (%) | 10 (37) | 25 (21.4) | 0.08 |
| Ventilator support, n (%) | 5 (18.5) | 3 (2.6) | 0.001 |
| ICU admission, n (%) | 6 (22.2) | 3 (2.6) | <0.001 |
| ICU admissions in hospitalized patients, n (%) | 6 (60) | 3 (12) | 0.02 |
| COVID-19 outcomes | |||
| Dead, n (%) | 8 (29.6) | 4 (3.3) | <0.001 |
| Dead in hospitalized patients, n (%) | 6 (60) | 4 (16) | 0.01 |
| Multiple logistic regression analysis for COVID-19-related death | |||
| OR (95% CI) | P | ||
| Males | 0.77 (0.16-3.69) | 0.747 | |
| Recipient age | 1.13 (1.03-1.24) | 0.008 | |
| Time from KT to COVID-19 | 0.99 (0.99-1.01) | 0.783 | |
| Fever | 14.39 (2.22-93.20) | 0.005 | |
| Fifth wave | 12.97 (2.33-72.12) | 0.003 | |
Comparison between those infected in June to November 2021 and December 2021 to February 2022.
CI, confidence interval; COVID-19, coronavirus disease 2019; ICU, intensive care unit; IQR, interquartile range; KT, kidney transplantation; mRNA, messenger RNA; mTOR, mammalian target of rapamycin; OR, odds ratio.